Relative Bioavailability of a Single Oral Dose of Nintedanib Given Alone and in Combination With Multiple Oral Doses of Rifampicin in Healthy Male Volunteers (an Open-label, Two-period, Fixed Sequence Phase I Trial)
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2014
At a glance
- Drugs Nintedanib (Primary) ; Rifampicin (Primary)
- Indications Cancer; Mycobacterial infections
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Jan 2013 New trial record
- 01 Jan 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.